NTSAD Community Voices | October 26, 2026

Nine Years of Collaboration, Commitment, and Progress: The LOTSS Think Tank

Nine years ago, a family determined to change the future for people living with late onset Tay-Sachs disease (LOTS) helped create something that did not exist before: a dedicated forum where leading researchers and clinicians could come together, share ideas, challenge assumptions, and work collectively toward better treatments for late-onset Tay-Sachs and Sandhoff diseases (LOTSS). 

That vision became the LOTSS Think Tank. 

Founded in 2018 and inspired by Alexis Buryk, whose twin daughters, Katie and Allie, both live with LOTS, the Think Tank has grown into an important annual gathering of researchers, clinicians, industry experts, and members of the LOTSS community. Supported by the Katie & Allie Buryk Research Fund at NTSAD, the meeting is designed to move beyond presentations to identify critical gaps, foster collaboration, and turn scientific discussion into action. 

A Family's Determination Creates Momentum 

The story of the LOTSS Think Tank begins with Katie and Allie's journey. 

After years of searching for an explanation for progressive symptoms, the twins were diagnosed with late-onset Tay-Sachs disease. In the wake of such a devastating diagnosis, and facing the absence of treatment options, the Buryk family was desperate to effect change. In 2014, they established the Katie & Allie Buryk Research Fund at NTSAD with a clear purpose: raise awareness, bring resources to an underfunded area of research, and help accelerate the search for treatments. 

Their determination has been extraordinary, and the support they have received has been inspiring. The fund has now raised more than $1.3 million for LOTSS research, supported multiple research projects, and established the LOTSS Think Tank as an ongoing scientific forum that attracts leading experts from around the world. 

The Buryk family's impact extends well beyond the dollars raised. They have helped bring visibility to the challenges faced by adults living with LOTSS and have consistently encouraged researchers and clinicians to keep the experiences of patients at the center of the work. Their commitment demonstrates what is possible when families, scientists, clinicians, and a patient advocacy organization come together around a shared goal. 

We realized, as a family, mostly driven by Katie motivating us into action, that we needed to find a treatment or a cure. We wanted to maximize the focus on Tay Sachs and with the help of Dr. Cynthia Tifft and Dr. Steve Walkley, and the support of NTSAD, we started the Think Tank.  – Alexis Buryk, Founder of the LOTSS Think Tank 

From Conversation to Collaboration 

Since 2018, the Think Tank has created a space for scientific exchange that is difficult to achieve in a condition as small and specialized as LOTSS. Researchers and clinicians have come together to discuss emerging therapeutic approaches, clinical trial readiness, natural history, outcome measures, biomarkers, and the complex neurological and psychiatric manifestations of the disease. 

The conversations have also helped identify areas where additional expertise was needed—and, importantly, have led to focused collaborations that extend well beyond the annual meeting. 

The LOTSS Think Tank's success is also a reflection of the leadership and commitment of its founding co-chairs, Cynthia Tifft, MD, PhD, of the National Human Genome Research Institute, and Steve Walkley, DVM, PhD, of Albert Einstein College of Medicine. From the beginning, Drs. Tifft and Walkley helped shape the Think Tank into a forum where researchers and clinicians could come together to tackle important challenges in LOTSS research. Following Dr. Walkley's retirement in 2026, Heather Gray-Edwards, DVM, of the University of Massachusetts Chan Medical School, has joined Dr. Tifft as co-chair, while he will continue his involvement as an advisor to the initiative. NTSAD is deeply grateful to the co-founders for their vision and leadership over the past eight years, and to Dr. Gray-Edwards for stepping into this role as the Think Tank enters its next chapter. 

"We began the LOTSS Think Tank to draw attention to late onset Tay-Sachs and Sandhoff diseases, conditions that at the time were simply not receiving the focus needed in order to make advances in treatment.  In addition to boosting attention to these conditions, a key goal was to emphasize the need for acceleration of research so that individuals living with LOTSS today could benefit as soon as possible.  These goals remain central to the Think Tank leadership and its members as we go forward." – Steve Walkley, DVM, PhD, LOTSS Think Tank Founding Co-chair

Two examples of how the Think Tank's conversations have evolved into sustained collaborations are the Psychiatric Working Group and the Biomarker Working Group. This year's presentations and patient panel discussion around mobility and exoskeletal devices will likely lead to another transformative initiative. 

Addressing the Psychiatric Impact of LOTSS 

Psychiatric symptoms can be among the earliest and most disabling manifestations of late-onset Tay-Sachs, yet clinicians have historically had limited disease-specific guidance for recognizing and managing them. The medical literature is limited, and symptoms can be mistaken for more common psychiatric conditions. 

A patient and caregiver discussion at a LOTSS Think Tank in 2023 helped bring this challenge into sharper focus. In response, a group of neurologists and psychiatrists came together to develop practical resources for healthcare providers caring for people with late-onset GM2 gangliosidosis. 

The resulting recommendations provide guidance for psychiatric providers on the treatment of psychiatric symptoms in LOTS, along with an acute-management resource for psychiatric emergencies. The working group has also identified additional opportunities for research, including collecting patient and caregiver perspectives and developing a case series and consensus guidance for the psychiatry community. 

This is an important example of the Think Tank's purpose in action: a challenge raised by the community becomes a conversation among experts, which becomes a collaboration, which becomes a resource that can help patients and families. 

Advancing Biomarker Research 

The Think Tank has also helped sustain focus on another critical piece of the treatment-development puzzle: biomarkers. 

For rare diseases, reliable biomarkers can be essential to understanding disease biology, measuring progression, and determining whether a therapy is having the intended effect. NTSAD's GM1 and GM2 Biomarker Working Group is working toward FDA recognition of cerebrospinal fluid GM1 and GM2 ganglioside levels as clinically relevant biomarkers—an important step that could support the development and evaluation of future therapies. 

The work reflects a broader lesson from the LOTSS Think Tank: advancing treatments requires more than developing a therapy itself. The field also needs meaningful ways to measure disease, understand change over time, and determine whether an intervention is working. 

"If we can convince the FDA with our collected evidence that GM1 and GM2 ganglioside levels in the cerebrospinal fluid are suitable surrogate biomarkers of drug efficacy, we will not only have a tool to better predict outcome but also spark the industry's interest in developing new treatments for these very rare but highly devastating diseases." – Mathias Schmidt, PhD, Co-Chair LOTSS Think Tank Biomarker Working Group 

Building Toward Treatments 

The progress in LOTSS research over the past eight years is encouraging. When the first Think Tank convened in 2018, significant gaps remained in the understanding of the disease, and therapeutic options were extremely limited. Today, researchers are pursuing new approaches to treatment while building the tools and knowledge needed to bring promising therapies into clinical development. 

One important example is the recent FDA authorization of a second-generation gene therapy clinical trial for GM2 gangliosidosis at the University of Massachusetts Chan Medical School, led by Principal Investigator Miguel Sena-Esteves, PhD. This milestone reflects years of research and the commitment of many partners to advancing GM2 gene therapy. In 2025, NTSAD awarded $365,000 to support the study as part of a collaborative effort that ultimately provided $870,000 from NTSAD's Research Initiative and three mission-aligned foundations. NTSAD's contribution was made possible with generous support from individuals and restricted fund holders—including the Katie & Allie Buryk Research Fund as well as the Cameron and Hayden Lord Foundation, Sussman Family Fund, Vera Pesotchinsky Research Fund, New York Area Fund, Heringer-Handwerker Research Fund, LOTS Research and Education Fund, and Roden family. 

The progress of this particular study represents an important development for the broader GM2 community. Advances in gene therapy, biomarkers, clinical rating scales, and trial readiness are helping to strengthen the foundation for therapeutic development across Tay-Sachs and Sandhoff diseases. 

The impact of the LOTSS Think Tank is reflected not only in scientific discoveries, but in the collaborations and new areas of investigation it has helped catalyze. The Psychiatric and Biomarker Working Groups are two examples of how ideas raised through the Think Tank can evolve into sustained efforts that address important unmet needs in the field. 

"When you put scientists and clinicians with common interests in the same room for the better part of two days, the result is a collective spark of genius that enkindles collaborative projects and accelerates a path forward for LOTSS and potentially many other rare diseases." – Cynthia Tifft, MD, PhD, LOTSS Think Tank Founding Co-chair 

Just as importantly, the Think Tank has created an enduring network of researchers and clinicians committed to advancing LOTSS research. Year after year, participants return to share new findings, challenge one another's thinking, identify unanswered questions, and determine where collaboration can make the greatest difference. That continuity matters in an ultra-rare disease, where progress depends on bringing together expertise and resources that no single researcher or institution can provide alone. 

A Family's Vision, A Community's Commitment 

At the heart of this effort is the extraordinary commitment of the Buryk family. What began with Alexis Buryk's determination to create a better future for her daughters, Katie and Allie, has grown into a sustained investment in the future of the entire LOTSS community. 

The Katie & Allie Buryk Research Fund has supported scientific investigation, helped bring experts together, and contributed to efforts ranging from the LOTSS Think Tank to broader GM2 therapeutic development. But the family's impact extends well beyond fundraising. Their persistence has helped ensure that the experiences and needs of adults living with LOTSS remain part of the scientific conversation. 

The Think Tank is a powerful example of what can happen when families, researchers, clinicians, donors, and a patient advocacy organization share a common commitment to progress. What began as one family's determination has become a growing community of people working together to better understand LOTSS, address the challenges faced by those living with the disease, and accelerate the search for effective treatments. 

NTSAD is deeply grateful to the Buryk family—and to every researcher, clinician, patient, caregiver, donor, and partner who has contributed to this effort since 2018. 

The questions are still significant. The challenges are real. But so is the progress. 

Eight years after the first LOTSS Think Tank, the commitment to advancing research remains stronger than ever. And the work continues. 

Share This Story, Choose Your Platform!

Support the Blog

Behind every post is a commitment to sharing reliable information, uplifting stories, and resources for families navigating rare diseases. Sponsorship directly supports this mission, helping us expand our reach, deepen our content, and continue providing a trusted space for our community.

Contact our Development Manager, Erin Demers, for more information